01 / Research notes
What the research can and cannot say
Laboratory and animal findings create hypotheses. They do not show that KPV treats inflammatory bowel disease, skin disease, or a wound in people. The right evaluation depends on the symptom and diagnosis, especially when inflammation could signal an infection or another condition needing established care.
02 / Research notes
Oral and topical questions
The HHS policy discusses oral and topical KPV acetate under its conditions. For an oral peptide formulation, the compounder is expected to document adequate human bioavailability for that specific formulation. A route named in the policy is not proof of an effective dose or clinical outcome.
03 / Research notes
Safety and sourcing
FDA has noted the lack of identified human exposure data for KPV products. Product identity, contamination, and unknown longer-term effects remain important questions. A clinical discussion should address established options first.
Evidence and safety in context
KPV is studied in laboratory and animal models of inflammation. Those results do not establish that a KPV product treats inflammatory bowel disease, skin problems, or wounds in people.
FDA says it lacks important information on potential human safety issues, including whether administration could cause harm. Oral KPV has an additional formulation-specific bioavailability condition in the HHS interim policy; a proposed route is not proof of clinical benefit.
Questions for a clinical visit
- What diagnosis explains the inflammation or skin symptom?
- What established care should be considered first?
- If an oral formulation is proposed, what human bioavailability evidence applies to that exact formulation?
See how the HHS policy works and how to prepare for a consultation.
Common questions about KPV
What are the benefits of KPV peptide?
Potential effects are being studied, but clinical benefits in humans have not been established.
Is oral KPV covered by the HHS policy?
The policy discusses qualifying oral KPV acetate and requires documentation of adequate human bioavailability for the specific oral formulation.
Is KPV FDA approved?
No. The interim policy does not approve KPV or any compounded KPV product.
Does KPV treat cancer?
No adequate human evidence establishes KPV as a cancer treatment. A cancer concern needs prompt evaluation by an appropriate clinician.
Are KPV injections covered by this HHS policy?
The interim policy discussed here identifies specified oral and topical KPV acetate forms. Do not assume another route is covered.
Important information
HHS's interim policy is conditional and may be revisited. Compounded products are not FDA approved and have not undergone FDA review for safety, effectiveness, or quality before marketing. Treatment through Jonathan Larson MDPC requires a clinical evaluation; a licensed provider decides whether any prescription is medically necessary and appropriate. This guide is informational and is not medical advice.
Read the HHS policy ↗